Published in J Med Genet on October 01, 1996
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet (1998) 1.88
Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene (2011) 1.69
BRCA1 variants in a family study of African-American and Latina women. Hum Genet (2005) 1.19
Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. J Med Genet (2006) 1.17
Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). BMC Cancer (2013) 0.88
Missense polymorphisms in the adenomatous polyposis coli gene and colorectal cancer risk. Dis Colon Rectum (2008) 0.83
Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients. BMC Med Genet (2014) 0.80
The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations. BMC Med Genet (2006) 0.79
Does the occurrence of certain rare cancers indicate an inherited cancer susceptibility? Fam Cancer (2003) 0.75
Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas. PLoS One (2016) 0.75
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (1994) 36.53
Identification of the breast cancer susceptibility gene BRCA2. Nature (1996) 17.14
Linkage of early-onset familial breast cancer to chromosome 17q21. Science (1990) 16.21
Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1993) 11.01
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994) 9.60
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 9.06
Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science (1994) 8.73
Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet (1991) 7.87
BRCA1 mutations in primary breast and ovarian carcinomas. Science (1994) 6.81
Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet (1991) 6.61
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet (1995) 5.83
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet (1995) 4.86
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA (1995) 4.45
Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet (1994) 4.15
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 3.81
Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet (1995) 3.71
Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet (1995) 3.61
Growth retardation and tumour inhibition by BRCA1. Nat Genet (1996) 3.47
Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet (1994) 3.38
Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet (1992) 3.13
A suggested nomenclature for designating mutations. Hum Mutat (1993) 3.10
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet (1995) 2.91
Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet (1994) 2.66
Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA (1995) 2.50
Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet (1995) 2.42
The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet (1995) 2.02
Inherited breast and ovarian cancer. Hum Mol Genet (1995) 1.87
Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet (1995) 1.85
Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res (1995) 1.85
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet (1996) 1.79
BRCA1 mutations in Ashkenazi Jewish women. Am J Hum Genet (1995) 1.75
Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis. UKCCCR Familial Ovarian Cancer Study Group. Am J Hum Genet (1996) 1.72
Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res (1994) 1.71
Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes Dev (1995) 1.61
A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am J Hum Genet (1996) 1.45
Dideoxy fingerprinting (ddE): a rapid and efficient screen for the presence of mutations. Genomics (1992) 1.43
Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res (1995) 1.43
Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet (1996) 1.42
Cancer mortality in relatives of women with breast cancer: the OPCS Study. Office of Population Censuses and Surveys. Int J Cancer (1996) 1.40
A P1-based physical map of the region from D17S776 to D17S78 containing the breast cancer susceptibility gene BRCA1. Hum Mol Genet (1994) 1.34
A human BRCA1 gene knockout. Nature (1995) 1.27
Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA. Hum Mol Genet (1993) 1.19
Hereditary and familial ovarian cancer in southern Ontario. Cancer (1994) 1.09
Cancer mortality in relatives of women with ovarian cancer: the OPCS Study. Office of Population Censuses and Surveys. Int J Cancer (1996) 1.05
Detection of BRCA1 mutations by the protein truncation test. Hum Mol Genet (1995) 1.05
Germline mutation of BRCA1 in Japanese breast cancer families. Cancer Res (1995) 1.02
Hereditary breast and ovarian cancer: epidemiology, genetics, screening and predictive testing. Clin Invest Med (1995) 0.89
Rapid and efficient screening for p53 gene mutations by dideoxy fingerprinting. Biotechniques (1995) 0.86
Construction of a genetic linkage map in man using restriction fragment length polymorphisms. Am J Hum Genet (1980) 75.25
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (1994) 36.53
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994) 9.60
BRCA1 mutations in primary breast and ovarian carcinomas. Science (1994) 6.81
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA (1996) 5.95
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet (2001) 5.08
A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA (1995) 4.45
Hereditary hemochromatosis. Phenotypic expression of the disease. N Engl J Med (1979) 4.09
Genetic linkage between hereditary hemochromatosis and HLA. Am J Hum Genet (1979) 3.96
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet (1996) 3.56
A mapped set of DNA markers for human chromosome 17. Genomics (1988) 3.55
Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet (1994) 3.38
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst (1999) 3.26
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet (1994) 3.05
CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet (2004) 3.03
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet (1996) 2.97
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet (1996) 2.93
BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol (1999) 2.79
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet (2000) 2.77
BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet (1996) 2.75
Critical illness myopathy and neuropathy. Lancet (1996) 2.71
Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer (2007) 2.62
A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer (1997) 2.53
Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol (2001) 2.41
Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet (1996) 2.40
Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med (2000) 2.39
Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet (1999) 2.36
P300-based brain computer interface: reliability and performance in healthy and paralysed participants. Clin Neurophysiol (2006) 2.36
Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer (1996) 2.33
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst (1998) 2.33
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet (2000) 2.31
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat (2008) 2.27
Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet (1997) 2.15
The impact of family history on early detection of prostate cancer. Nat Med (1995) 2.14
Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet (1999) 2.14
Utah pedigree studies: design and preliminary data for premature male CHD deaths. Prog Clin Biol Res (1979) 2.11
Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads. Mol Endocrinol (1991) 2.07
Cytologic identification of clinically occult proliferative breast disease in women with a family history of breast cancer. Am J Clin Pathol (1991) 2.07
BRCA1 and BRCA2 mutations and the risk for colorectal cancer. Clin Genet (2014) 2.02
A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol (2001) 2.01
On being the right size: a reappraisal of mammography trials in Canada and Sweden. Lancet (1997) 1.94
DNA screening for breast/ovarian cancer susceptibility based on linked markers. A family study. Arch Intern Med (1993) 1.91
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet (1998) 1.88
Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke (1996) 1.84
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res (2001) 1.81
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet (1996) 1.79
The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology. Steroids (1997) 1.76
BRCA1 mutations in Ashkenazi Jewish women. Am J Hum Genet (1995) 1.75
Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet (2005) 1.71
Tightly linked markers for the neurofibromatosis type 1 gene. Genomics (1987) 1.68
A breast-ovarian cancer susceptibility gene maps to chromosome 17q21. Am J Hum Genet (1993) 1.66
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet (1998) 1.61
Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res (2000) 1.57
DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol (2001) 1.57
Non-random transmission of mutant alleles to female offspring of BRCA1 carriers in Poland. J Med Genet (2003) 1.57
Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet (1997) 1.55
The role of muscle biopsy in investigating isolated muscle pain. Neurology (2007) 1.54
V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology (2001) 1.54
Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol (2000) 1.54
In-situ breast cancer and BRCA1. Lancet (1996) 1.52
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer (2011) 1.51
Is dehydroepiandrosterone a hormone? J Endocrinol (2005) 1.46
A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am J Hum Genet (1996) 1.45
Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat (2007) 1.44
Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet (1997) 1.42
Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet (1996) 1.42
Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat (2005) 1.41
Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13. Genomics (1996) 1.41
An adult-onset myopathy characterized by a double ring appearance of muscle fibers. Neuromuscul Disord (1991) 1.38
The genetic aspects of neurofibromatosis. Ann N Y Acad Sci (1986) 1.38
Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev (2001) 1.35
Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab (2001) 1.35
DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids (1998) 1.35
Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet (1998) 1.35
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat (2014) 1.35
Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2004) 1.34
A P1-based physical map of the region from D17S776 to D17S78 containing the breast cancer susceptibility gene BRCA1. Hum Mol Genet (1994) 1.34
High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer (1995) 1.34
The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer (2012) 1.34
BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat (2006) 1.33
High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst (1994) 1.33
Screening for multiple endocrine neoplasia type 2a with DNA-polymorphism analysis. N Engl J Med (1989) 1.32
Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res (1997) 1.32
p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6. Nucleic Acids Res (1999) 1.31
Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12-q21. Nat Genet (1996) 1.30